The Effects of Postoperative Trimetazidine Treatment on Ischemia-Reperfusion Injury after Isolated Surgical Myocardial Revascularization
References
- Naviaux RK. Metabolic features and regulation of the healing cycle—A new model for chronic disease pathogenesis and treatment. Mitochondrion. 2018;46:278–297. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.mito.2018.08.001" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.mito.2018.08.001</a></pub-id>
- Ballinger SW, Patterson C, Knight-Lozano CA, et al. Mitochondrial Integrity and Function in Atherogenesis. Circulation. 2002;106:544–549. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1161/01.cir.0000023921.93743.89" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1161/01.cir.0000023921.93743.89</a></pub-id>
- Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science. 1992;256:628–632. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1126/science.1533953" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1126/science.1533953</a></pub-id>
- Yu E, Calvert PA, Mercer JR, et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation. 2013;128:702–712. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1161/CIRCULATIONAHA.113.002271" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1161/CIRCULATIONAHA.113.002271</a></pub-id>
- Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006;70(2):181–190. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.cardiores.2006.02.025" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.cardiores.2006.02.025</a></pub-id>
- Dhalla NS, Elmoselhi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res. 2000;47(3):446–56. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/s0008-6363(00)00078-x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/s0008-6363(00)00078-x</a></pub-id>
- Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92–100. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1172/JCI62874" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1172/JCI62874</a></pub-id>
- Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. 1998;38(2):291–300. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/s0008-6363(98)00033-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/s0008-6363(98)00033-9</a></pub-id>
- Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study. J Am Coll Cardiol. 1995 Oct;26(4):895–899. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/0735-1097(95)00280-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/0735-1097(95)00280-4</a></pub-id>
- Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation. 1996;94:135–142. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1161/01.cir.94.2.135" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1161/01.cir.94.2.135</a></pub-id>
- Boden WE, O’rourke RA, Teo KK, et al.; COURAGE trial coprincipal investigators and study coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE trial). Am Heart J. 2006;151:1173–1179. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ahj.2005.08.015" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ahj.2005.08.015</a></pub-id>
- Task Force Members; Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1093/eurheartj/eht296" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/eurheartj/eht296</a></pub-id>
- Lisboa da Silva RMF. Additional and emerging drugs for standard therapy for patients with stable angina. E-Journal of Cardiology Practice. 2017;15(11).
- Kallistratos MS, Poulimenos LE, Manolis AJ. Stable angina pectoris: which drugs or combinations to use in which patients. E-Journal of Cardiology Practice. 2017;15(8).
- Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580–588. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1161/01.res.86.5.580" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1161/01.res.86.5.580</a></pub-id>
- Di Napoli P, Chierchia S, Taccardi AA, et al. Trimetazidine improves postischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide. 2007;16:228–236. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.niox.2006.09.001" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.niox.2006.09.001</a></pub-id>
- Fragasso G, Piatti Md PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146(5):E18. doi: <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/S0002-8703(03)00415-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S0002-8703(03)00415-0</a></pub-id>
Language: English
Page range: 89 - 94
Submitted on: Jun 25, 2024
Accepted on: Sep 15, 2024
Published on: Sep 30, 2024
Published by: Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2024 Stanev Kamen, Dobreva-Yatseva Bistra, Gonovski Todor, Ivanov Asen, Nachev Gencho, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.